Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryoko Ihara

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Brain and Nerve = Shinkei Kenkyu No Shinpo|July 26, 2017
[Current Clinical Assessment Scales and Cognitive Tests in Global Clinical Studies on Alzheimer's Disease]Ryoko Ihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 31, 2016
[New diagnostic guidelines for Alzheimer's disease by NIA/AA]Ryoko Ihara
The Journal of Prevention of Alzheimer'S Disease|April 19, 2026
Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care systemMasanori Kurihara, Ryoko Ihara, Kenichiro Sato, et al.
Journal of Alzheimer'S Disease Reports|December 25, 2025
National trends in cerebrospinal fluid biomarker testing for Alzheimer's disease in JapanMasanori Kurihara, Ryoko Ihara, Kenichiro Sato, et al.
Journal of Alzheimer'S Disease Reports|September 4, 2025
Cost-benefit of dementia insurance for cognitively-unimpaired <i>APOE</i> ε4 homozygotes: A simulation studyKenichiro Sato, Saki Nakashima, Yoshiki Niimi, et al.
Clinical Nuclear Medicine|July 24, 2024
Clinical Application of 18 F-THK5351 PET to Image Ongoing Astrogliosis in MSA-P and MSA-CSoichiro Kondo, Kenji Ishibashi, Kenji Ishii, et al.
Biomedicines|August 29, 2024
Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer's Disease TreatmentKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease : JAD|September 13, 2024
Adverse Events as a Cause of Unblinding of Allocated Arms in Anti-Amyloid Therapy Trials: A Meta-Analysis of the Predictive ValueKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
JAR Life|July 30, 2025
How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodiesKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease Reports|June 11, 2025
Audio review as a measure of quality assurance and control of cognitive assessments in Alzheimer's disease studies: An experience from Japanese Trial-Ready Cohort StudyKenichiro Sato, Ryoko Ihara, Yoshiki Niimi, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Brain and Nerve = Shinkei Kenkyu No Shinpo|July 26, 2017
[Current Clinical Assessment Scales and Cognitive Tests in Global Clinical Studies on Alzheimer's Disease]Ryoko Ihara
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 31, 2016
[New diagnostic guidelines for Alzheimer's disease by NIA/AA]Ryoko Ihara
The Journal of Prevention of Alzheimer'S Disease|April 19, 2026
Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care systemMasanori Kurihara, Ryoko Ihara, Kenichiro Sato, et al.
Journal of Alzheimer'S Disease Reports|December 25, 2025
National trends in cerebrospinal fluid biomarker testing for Alzheimer's disease in JapanMasanori Kurihara, Ryoko Ihara, Kenichiro Sato, et al.
Journal of Alzheimer'S Disease Reports|September 4, 2025
Cost-benefit of dementia insurance for cognitively-unimpaired <i>APOE</i> ε4 homozygotes: A simulation studyKenichiro Sato, Saki Nakashima, Yoshiki Niimi, et al.
Clinical Nuclear Medicine|July 24, 2024
Clinical Application of 18 F-THK5351 PET to Image Ongoing Astrogliosis in MSA-P and MSA-CSoichiro Kondo, Kenji Ishibashi, Kenji Ishii, et al.
Biomedicines|August 29, 2024
Regional Variability in MRI Scans with Different Magnetic Field Strengths in Japan: Implications for Healthcare Preparedness for Alzheimer's Disease TreatmentKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease : JAD|September 13, 2024
Adverse Events as a Cause of Unblinding of Allocated Arms in Anti-Amyloid Therapy Trials: A Meta-Analysis of the Predictive ValueKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
JAR Life|July 30, 2025
How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodiesKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease Reports|June 11, 2025
Audio review as a measure of quality assurance and control of cognitive assessments in Alzheimer's disease studies: An experience from Japanese Trial-Ready Cohort StudyKenichiro Sato, Ryoko Ihara, Yoshiki Niimi, et al.
Pageof 6